AAV-Mediated Fgf21 Gene Therapy Promotes Healthspan Extension By Whole-Body Tissue-Specific Adaptations
Scientists have explored a novel approach to combat the effects of aging by utilizing a gene therapy that introduces a specific hormone into the body. This hormone, called Fibroblast Growth Factor 21 (FGF21), is naturally involved in regulating how our bodies use energy and maintain metabolic balance.
The therapy involves using a modified, harmless virus, known as an adeno-associated virus (AAV), as a delivery system. This AAV carries the genetic instructions for producing FGF21 directly into muscle cells. In a recent study, this treatment was administered to older mice.
The results were quite remarkable: the treated mice showed a sustained increase in FGF21 levels in their bloodstream, which led to an extension of both their healthy years and overall lifespan. Beyond just living longer, the mice also experienced a reversal of several common age-related problems, including resistance to insulin (a precursor to diabetes), unwanted weight gain, and a decline in both muscle strength and cognitive abilities. The therapy even influenced gene activity in key organs involved in metabolism and in the brain.
These findings suggest that this gene therapy holds significant promise as a potential strategy to promote healthier aging in the future.
Source: link to paper